BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 37459849)

  • 1. Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques.
    Czarnywojtek A; Borowska M; Dyrka K; Van Gool S; Sawicka-Gutaj N; Moskal J; Kościński J; Graczyk P; Hałas T; Lewandowska AM; Czepczyński R; Ruchała M
    Pharmacology; 2023; 108(5):423-431. PubMed ID: 37459849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standard therapy or additionally radioactive iodine (131I) therapy; which will stop the recurrence of glioblastoma multiforme (GBM)?
    Czarnywojtek A; Gut P; Dyrka K; Sowiński J; Sawicka-Gutaj N; Katulska K; Stajgis P; Wykrętowicz M; Moskal J; Kościński J; Pietrończyk K; Graczyk P; Krawczyński MR; Florek E; Szczepanek-Parulska E; Ruchała M; Ferlito A
    Endokrynol Pol; 2024; 75(2):130-139. PubMed ID: 38646982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.
    Baugh R; Khalique H; Page E; Lei-Rossmann J; Wan PK; Johanssen T; Ebner D; Ansorge O; Seymour LW
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38724464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma.
    Tobias AL; Thaci B; Auffinger B; Rincón E; Balyasnikova IV; Kim CK; Han Y; Zhang L; Aboody KS; Ahmed AU; Lesniak MS
    Stem Cells Transl Med; 2013 Sep; 2(9):655-66. PubMed ID: 23926209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas.
    Estevez-Ordonez D; Chagoya G; Salehani A; Atchley TJ; Laskay NMB; Parr MS; Elsayed GA; Mahavadi AK; Rahm SP; Friedman GK; Markert JM
    Neurosurg Clin N Am; 2021 Apr; 32(2):265-281. PubMed ID: 33781507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy.
    Stepanenko AA; Sosnovtseva AO; Valikhov MP; Chernysheva AA; Abramova OV; Naumenko VA; Chekhonin VP
    Front Immunol; 2024; 15():1326757. PubMed ID: 38390330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of immune cells in oncolytic herpes simplex virotherapy for glioma.
    Otani Y; Yoo JY; Shimizu T; Kurozumi K; Date I; Kaur B
    Brain Tumor Pathol; 2022 Apr; 39(2):57-64. PubMed ID: 35384530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme.
    Kazemi Shariat Panahi H; Dehhaghi M; Lam SS; Peng W; Aghbashlo M; Tabatabaei M; Guillemin GJ
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):1122-1142. PubMed ID: 34004331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
    Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zika Virus: A Neurotropic Warrior against High-Grade Gliomas-Unveiling Its Potential for Oncolytic Virotherapy.
    Calderón-Peláez MA; Maradei Anaya SJ; Bedoya-Rodríguez IJ; González-Ipuz KG; Vera-Palacios D; Buitrago IV; Castellanos JE; Velandia-Romero ML
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Immunotherapeutic Approaches for Glioblastoma.
    Vázquez Cervantes GI; González Esquivel DF; Gómez-Manzo S; Pineda B; Pérez de la Cruz V
    J Immunol Res; 2021; 2021():3412906. PubMed ID: 34557553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing of Zika virus live-attenuated vaccine (ZIKV-LAV) strains as oncolytic viruses targeting human glioblastoma multiforme cells.
    Victorio CBL; Novera W; Ganasarajah A; Ong J; Thomas M; Wu J; Toh HSY; Sun AX; Ooi EE; Chacko AM
    J Transl Med; 2024 Feb; 22(1):126. PubMed ID: 38308299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy and virotherapy: novel therapeutic approaches for brain tumors.
    Kroeger KM; Muhammad AK; Baker GJ; Assi H; Wibowo MK; Xiong W; Yagiz K; Candolfi M; Lowenstein PR; Castro MG
    Discov Med; 2010 Oct; 10(53):293-304. PubMed ID: 21034670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
    Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
    BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in immunotherapy for glioblastoma multiforme.
    Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
    Front Immunol; 2022; 13():944452. PubMed ID: 36311781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates.
    Wollmann G; Ozduman K; van den Pol AN
    Cancer J; 2012; 18(1):69-81. PubMed ID: 22290260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.